The Canadian Intellectual Property Office has allowed the parent patent and the Continuation in Part with additional commercially viable technology claims for the use of galantamine as a Method of Treating Organophosphorus Poisioning.
The Canadian Intellectual Property Office has allowed the parent patent and the Continuation in Part with additional commercially viable technology claims for the use of galantamine as a Method of Treating Organophosphorus Poisioning.